Tissue factor pathway inhibitor 2 (TFPI2) is frequently silenced by aberrant promoter hypermethylation in gastric cancer

Cancer Genetics and Cytogenetics

Volumn 197, Issue 1, 2010, Pages 16-24

  Takada, Hisashi ^a   Wakabayashi, Naoki ^a   Dohi, Osamu ^a   Yasui, Kohichiroh ^a   Sakakura, Chouhei ^a   Mitsufuji, Shoji ^a   Taniwaki, Masafumi ^a   Yoshikawa, Toshikazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; MESSENGER RNA; PLACENTA PROTEIN 5; TRICHOSTATIN A;

AGED; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROMOTER REGION; STOMACH CANCER;

ADULT; AGED; AZACITIDINE; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE SILENCING; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; STOMACH NEOPLASMS;

EID: 74749100743     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.11.004     Document Type: Article

References (44)

1. Larsen F., Gundersen G., Lopez R., and Prydz H. CpG islands as gene markers in the human genome. Genomics 13 (1992) 1095-1107
2. Jones P.A., and Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 3 (2002) 415-428
3. Strathdee G., and Brown R. Aberrant DNA methylation in cancer: potential clinical interventions. Expert Rev Mol Med 4 (2002) 1-17
4. Toyota M., Ahuja N., Suzuki H., Itoh F., Ohe-Toyota M., Imai K., Baylin S.B., and Issa J.P. Aberrant methylation in gastric cancer associated with the CpG island methylate phenotype. Cancer Res 59 (1999) 5438-5442
5. INK4a expression in gastric adenocarcinoma. Int J Cancer 87 (2000) 236-240
6. Grady W.M., Willis J., Guilford P.J., Dungier A.K., Toro T.T., Lynch H., Wisner G., Ferguson K., Eng C., Park J.G., Kim S.J., and Markowitz S. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 26 (2000) 16-17
7. Li L.Q., Ito K., Sakkara C., Fukamachi H., Inoue K., Chi X.Z., Lee K.Y., Nomura S., Lee C.W., Han S.B., Kim H.M., Kim W.J., Yamamoto H., Yamashita N., Yano T., Ikeda T., Itohara S., Inazawa J., Abe T., Hagiwara A., Yamagishi H., Ooe A., Kaneda A., Sugimura T., Ushijima T., Bae S.C., and Ito Y. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109 (2002) 113-124
8. Kim T.Y., Jung H.S., Song S.H., Dimtchev A., Jeong S.J., Lee J.W., Kim T.Y., Kim N.K., Jung M., and Bang Y. Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. Oncogene 22 (2003) 3943-3951
9. Takada H., Imoto I., Tsuda H., Nakanishi Y., Ichikura T., Mochizuki H., Mitsufuji S., Hosoda F., Hirohashi S., Ohki M., and Inazawa J. ADAM23, a possible tumor suppressor gene, is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter hypermethylation. Oncogene 24 (2005) 8051-8060
10. Nojima M., Suzuki H., Toyota M., Watanabe Y., Maruyama R., Sasaki S., Sasaki Y., Mita H., Nishikawa N., Yamaguchi K., Hirata K., Itoh F., Tokino T., Mori M., Imai K., and Shinomura Y. Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene 26 (2007) 4699-4713
11. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 5 (2005) 223-231
12. Suzuki H., Gabrielson E., Chen W., Anbazhagan R., van Engeland M., Weijenberg M.P., Herman J.G., and Baylin S.B. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 31 (2002) 141-149
13. Sato N., Parker A.R., Fukushima N., Miyagi Y., Iacobuzio-Donahue C.A., Eshleman J.R., and Goggins M. Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene 24 (2005) 850-858
14. Nobeyama Y., Okochi-Takada E., Furuta J., Miyagi Y., Kikuchi K., Yamamoto A., Nakanishi Y., Nakagawa H., and Ushijima T. Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. Int J Cancer 121 (2007) 301-307
15. Wong C.M., Ng Y.L., Lee J.M., Wong C.C., Cheung O.F., Chan C.Y., Tung E.K., Ching Y.P., and Ng I.O. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 45 (2007) 1129-1138
16. Jee C.D., Kim M.A., Jung E.J., Kim J., and Kim W.H. Identification of genes epigenetically silenced by CpG methylation in human gastric carcinoma. Eur J Cancer 45 (2009) 1282-1293
17. Wojtukiewicz M.Z., Sierko E., Zimnoch L., Kozlowski L., and Kisiel W. Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. Thromb Haemost 90 (2003) 140-146
18. Hojo H. Establishment of cultured cell lines of human stomach cancer: origin and their morphological characteristics [In Japanese]. Niigata Igakukai Zasshi 91 (1977) 737-752
19. Motoyama T., Hojo H., and Watanabe H. Comparison of seven cell lines derived from human gastric carcinomas. Acta Pathol Jpn 36 (1986) 65-83
20. Ochiai A., Yasui W., and Tahara E. Growth-promoting effect of gastrin on human gastric carcinoma cell line TMK-1. Jpn J Cancer Res 76 (1985) 1064-1071
21. Akiyama S., Amo H., Watanabe T., Matsuyama M., Sakamoto J., Imaizumi M., Ichihashi H., Kondo T., and Takagi H. Characteristics of three human gastric cancer cell lines, NU-GC-2, NU-GC-3 and NU-GC-4. Jpn J Surg 18 (1988) 438-446
22. Park J.G., Frucht H., LaRocca R.V., Bliss Jr. D.P., Kurita Y., Chen T.R., Henslee J.G., Trepel J.B., Jensen R.T., Johnson B.E., Bang Y., Kim J.P., and Gazdar A.F. Characteristics of cell lines established from human gastric carcinoma. Cancer Res 50 (1990) 2773-2780
23. Sekiguchi M., Sakakibara K., and Fujii G. Establishment of cultured cell lines derived from a human gastric carcinoma. Jpn J Exp Med 48 (1978) 61-68
24. Takada H., Imoto I., Tsuda H., Sonoda I., Ichikura T., Mochizuki H., Okanoue T., and Inazawa J. Screening of DNA copy-number aberrations in gastric cancer cell lines by array-based comparative genomic hybridization. Cancer Sci 96 (2005) 100-110
25. Xiong Z., and Laird P.W. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 25 (1997) 2532-2534
26. Lauren P. The two histological main types of gastric adenocarcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 64 (1965) 31-49
27. Baylin S.B., Herman J.G., Graff J.R., Vertino P.M., and Issa J.P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72 (1998) 141-196
28. Miyagi Y., Koshikawa N., Yasumitsu H., Miyagi E., Hirahara F., Aoki I., Misugi K., Umeda M., and Miyazaki K. cDNA cloning and mRNA expression of a serine proteinase inhibitor secreted by cancer cells: identification as placental protein 5 and tissue factor pathway inhibitor-2. J Biochem 116 (1994) 939-942
29. Sprecher C.A., Kisiel W., Mathewes S., and Foster D.C. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc Natl Acad Sci U S A 91 (1994) 3353-3357
30. Rao C.N., Liu Y.Y., Peavey C.L., and Woodley D.T. Novel extracellular matrix-associated serine proteinase inhibitors from human skin fibroblasts. Arch Biochem Biophys 317 (1995) 311-314
31. Petersen L.C., Sprecher C.A., Foster D.C., Blumberg H., Hamamoto T., and Kisiel W. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Biochemistry 35 (1996) 266-272
32. Miyagi Y., Yasumitsu H., Eki T., Miyata S., Kkawa N., Hirahara F., Aoki I., Misugi K., and Miyazaki K. Assignment of the human PP5/TFPI-2 gene to 7q22 by FISH and PCR-based human/rodent cell hybrid mapping panel analysis. Genomics 35 (1996) 267-268
33. Yanamandra N., Kondraganti S., Gondi C.S., Gujrati M., Olivero W.C., Dinh D.H., and Rao J.S. Recombinant adeno-associated virus (rAAV) expressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line. Int J Cancer 115 (2005) 998-1005
34. Tamura G., Sakata K., Nishizuka S., Maesawa C., Suzuki Y., Terashima M., Eda Y., and Satodate R. Allelotype of adenoma and differentiated adenocarcinoma of the stomach. J Pathol 180 (1996) 371-377
35. Nishizuka S., Tamura G., Terashima M., and Satodate R. Commonly deleted region on the long arm of chromosome 7 in differentiated adenocarcinoma of the stomach. Br J Cancer 76 (1997) 1567-1571
36. Weng D.S., Li J.T., Mai S.J., Pan Z.Z., Feng B.J., Feng Q.S., Huang L.X., Wang Q.J., Li Y.Q., Yu X.J., Chen S.P., He J., and Xia J.C. Identification of a new target region on the long arm of chromosome 7 in gastric carcinoma by loss of heterozygosity. World J Gastroenterol 12 (2006) 2437-2440
37. Jiang P., Watanabe H., Okada G., Ohtsubo K., Mouri H., Tsuchiyama T., Yao F., and Sawabu N. Diagnostic utility of aberrant methylation of tissue factor pathway inhibitor 2 in pure pancreatic juice for pancreatic carcinoma. Cancer Sci 97 (2006) 1267-1273
38. Steiner F.A., Hong J.A., Fischette M.R., Beer D.G., Guo Z.S., Chen G.A., Weiser T.S., Kassis E.S., Nguyen D.M., Lee S., Trepel J.B., and Schrump D.S. Sequential 5-aza 2′-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells. Oncogene 24 (2005) 2386-2397
39. Rollin J., Iochmann S., Bléchet C., Hubé F., Régina S., Guyétant S., Lemarié E., Reverdiau P., and Gruel Y. Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer. Br J Cancer 92 (2005) 775-783
40. Rao C.N., Segawa T., Navari J.R., Xu L., Srivastava S., Moul J.W., and Phillips B. Methylation of TFPI-2 gene is not the sole cause of its silencing. Int J Oncol 22 (2003) 843-848
41. Konduri S.D., Rao C.N., Chandrasekar N., Tasiou A., Mohanam S., Kin Y., Lakka S.S., Dinh D., Olivero W.C., Gujrati M., Foster D.C., Kisiel W., and Rao J.S. A novel function of tissue factor pathway inhibitor-2 (TFPI-2) in human glioma invasion. Oncogene 20 (2001) 6938-6945
42. Konduri S.D., Tasiou A., Chandrasekar N., and Rao J.S. Overexpression of tissue factor pathway inhibitor-2 (TFPI-2) decreases the invasiveness of prostate cancer cells in vitro. Int J Oncol 18 (2001) 127-131
43. George J., Gondi C.S., Dinh D.H., Gujrati M., and Rao J.S. Restoration of tissue factor pathway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosis. Clin Cancer Res 13 (2007) 3507-3517
44. Ivanciu L., Gerard R.D., Tang H., Lupu F., and Lupu C. Adenovirus-mediated expression of tissue factor pathway inhibitor-2 inhibits endothelial cell migration and angiogenesis. Arterioscler Thromb Vasc Biol 27 (2007) 310-316